+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer



Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer



Clinical Cancer Research 15(5): 1794-1800



This study was conducted to investigate the impact of functional polymorphisms in the FAS and FASL genes on the survival of early stage non-small cell lung cancer (NSCLC) patients. Three hundred and thirty-eight consecutive patients with surgically resected NSCLC were enrolled. The FAS -1377G>A (rs2234767) and -670A>G (rs1800682) and FASL -844C>T (rs763110) polymorphisms were investigated. Immunohistochemistry was used to assess FAS protein expression in tumors. The genotype and haplotype associations with survival were analyzed using Cox proportional hazards model, Kaplan-Meier method, and the log-rank test. Patients with the GG and combined AG+GG genotypes of the FAS -670A>G locus had a significantly decreased survival when compared with patients with the AA genotype [adjusted hazard ratio=1.71, 95% confidence interval (95% CI)=1.06-2.77, and P=0.03; and adjusted hazard ratio=1.48, 95% CI=1.01-2.20, and P=0.047, respectively]. In addition, the FAS -1377G/-670G and -1377A/-670G haplotypes exhibited a significantly lower survival compared with the -1377G/-670A haplotype (adjusted hazard ratio=1.87, 95% CI=1.20-2.91, and P=0.006; and adjusted hazard ratio=1.31, 95% CI=1.05-1.65, P=0.02, respectively). Strongly positive FAS immunostaining was significantly less frequent in patients with the FAS -670 AG+GG genotype than in patients with the -670 AA genotype (4.5% versus 10.8%; P=0.04). The FAS -670A>G polymorphism may affect survival in early-stage NSCLC. The analysis of the FAS -670A>G polymorphism can help identify patients at high risk for a poor disease outcome.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055047388

Download citation: RISBibTeXText

PMID: 19240174

DOI: 10.1158/1078-0432.ccr-08-1770


Related references

Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. Journal of Clinical Oncology 27(34): 5823-5829, 2009

Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer. Annals of Surgical Oncology 17(10): 2608-2618, 2010

VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. Journal of Clinical Oncology 26(6): 856-862, 2008

AKT1 polymorphisms and survival of early stage non-small cell lung cancer. Journal of Surgical Oncology 105(2): 167-174, 2012

Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_Suppl): 9524-9524, 2016

Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiology Biomarkers and Prevention 15(11): 2239-2245, 2006

Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Science 101(11): 2436-2442, 2010

A case of long-term survival with stage IV small cell lung cancer and early-stage central-type squamous cell lung cancer treated by photodynamic therapy. Japanese Journal of Clinical Oncology 29(1): 45-48, 1999

Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clinical Cancer Research 12(18): 5448-5453, 2006

Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer 74(2): 164-169, 2011

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy. Oncology Letters 14(6): 8171-8177, 2017

Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer. Neoplasma 58(3): 245-250, 2011

Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population. Lung Cancer 73(1): 32-37, 2011

Survival in early-stage non-small cell lung cancer. Annals of Thoracic Surgery 60(2): 466-472, 1995

Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. Journal of Medical Genetics 42(6): 479-484, 2005